What does PD-L1 positive or negative mean?
Authors:
Open Access
- 30 November 2016
- journal article
- review article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 213 (13) , 2835-2840
Abstract
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti–PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.Keywords
Funding Information
- National Cancer Institute
- National Institutes of Health (R35 CA197633, P01 CA168585, 1U54 CA199090, R01 CA170689)
- Stand Up To Cancer (SU2C-AACR-DT1012)
- American Society of Clinical Oncology
- Tower Cancer Research Foundation
- The Hope Foundation
- UCLA
This publication has 47 references indexed in Scilit:
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJAMA, 2016
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patientsVirchows Archiv, 2016
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsCancer Discovery, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in HumansClinical Cancer Research, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNγ-induced apoptosisGene Therapy, 2003
- PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cellsProceedings of the National Academy of Sciences, 2003